Market authorizations for the drugs “Nebivolol-Nanolek” and “Ramipril” were issued by the Ministry of health of the Republic of Uzbekistan. Market authorizations shall remain valid for a period of 5 years.

Nebivolol-Nanolek is used to treat arterial hypertension, coronary heart disease, and angina of effort. Apart from treatment of hypertension, Ramipril is used for the treatment and prevention of myocardial infarction, diabetic nephropathy, diffuse renal diseases and chronic heart failure.

The Republic of Uzbekistan became the fourth export country in a row. Earlier, NANOLEK received market authorizations for various drugs intended for export to the Republic of Belarus, the Republic of Kazakhstan and the Republic of Azerbaijan.

Maxim Stetsyuk, Executive Director of NANOLEK: “These market authorizations will help us expand the territory of our export shipments, which is a sign that our products are in demand outside of Russia.”